Multispecific Drug Conjugates Combat Tumor Heterogeneity & Resistance
- Scientific rationale for TwoStep Therapeutics’ multi-specific targeting agent “PIP” and how it enables broad applicability across solid tumors
- Preclinical development of PIP-drug conjugates, their efficacy and safety, and comparison to clinical benchmarks
- Comparing the data from a single vs multi-targeted approach to highlight the rationale of multi-specific targeting